Mounjaro 2.5mg injection: what to expect from the starter dose

Your first pen has arrived, here is what is happening in your body

Picture opening the box, tucking the pen into the fridge door next to the milk, and wondering whether it is actually doing anything. It is, just not in the way you might expect. At 2.5mg, tirzepatide begins activating your GIP and GLP-1 receptors, which are involved in appetite regulation and the rate at which your stomach empties. Your brain starts receiving signals about fullness a little earlier than it used to. Gastric emptying slows slightly. Hunger cues become quieter.

What 2.5mg is not designed to do is deliver the weight-loss results seen in clinical trials. Those are associated with the maintenance doses further up the schedule. The 2.5mg Mounjaro injection pen is the system's settling-in period, your prescriber starts you here to reduce the likelihood of nausea, vomiting and other gastrointestinal effects that can be more pronounced if a higher dose is introduced straight away. The full Mounjaro dose schedule runs from 2.5mg through to 15mg, each step typically four weeks apart. The first step simply has a different purpose from all the ones that follow.

According to the NHS's patient information for tirzepatide, the most common side effects are gastrointestinal, nausea, diarrhoea, constipation and indigestion among them. These are generally most noticeable when starting or after a dose increase, and often settle within the first couple of weeks. The NHS tirzepatide page covers the full side-effect profile in plain language.

How long you stay at 2.5mg, and what drives the next decision

Most people spend four weeks at 2.5mg before moving to the 10mg dose, assuming they are tolerating treatment well. That timing is not arbitrary: it mirrors the prescribing schedule in the Mounjaro Summary of Product Characteristics and reflects how long the body typically takes to adjust at each level.

The move upward is not automatic. At nume, a GPhC-registered Independent Prescriber reads your repeat request and clinical information before any dose change is confirmed, a person, not software, makes that call. If side effects have been significant or your health picture has shifted, staying at 2.5mg a little longer may be the right clinical decision.

A question our prescribers hear fairly often: can you take two 2.5mg pens instead of stepping up to 5mg? It is worth reading the clinical reasoning on that question directly rather than guessing, the short answer is that it is not how the medicine is licensed or designed to be used. The 5mg pen is a single, correctly formulated dose rather than a doubled starter.

If you want a broader sense of where each dose sits in the treatment arc, the 5mg dose page explains what changes once the tolerability phase is behind you.

Who is prescribed the 2.5mg starter dose, and what eligibility looks like

Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Everyone who is prescribed tirzepatide starts at 2.5mg regardless of their starting weight or BMI, the dose schedule is the same for all patients.

BMI alone does not guarantee that tirzepatide is the right fit. A prescriber considers your full medical history, any medicines you are already taking, and conditions that might affect suitability. Mounjaro is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for use in people under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma) also require careful prescriber discussion before treatment can begin.

NICE's appraisal of tirzepatide (TA1026) sets out the NHS eligibility thresholds for publicly funded treatment, which are more restrictive than the licensed criteria. NICE TA1026 is worth reading if you want to understand how NHS access works alongside the private route. If you would like a sense of what private treatment involves day to day, our treatment overview sets that out.

Cost context: how the 2.5mg pen fits into the wider pricing picture

The 2.5mg pen covers four weeks of injections. Private prices for Mounjaro vary by dose and provider; lower doses have generally carried lower prices, though the gap between doses narrowed after Eli Lilly revised UK list prices in September 2025. If you are thinking about the longer-term cost of treatment across the full titration schedule, our Mounjaro cost page goes into the detail honestly, including what a single transparent private price should cover.

The starter dose is also where people sometimes wonder whether there is a cheaper route, buying without a clinical assessment. It bears saying plainly: tirzepatide is a prescription-only medicine. Pens sold through social media or websites that do not require a clinical assessment carry real risks; the MHRA has warned publicly about counterfeit weight-loss pens entering the UK, some of which have contained insulin rather than the labelled medicine. If a source cannot be verified on the GPhC pharmacy register, that is a serious red flag.

If you would like a prescriber to assess whether Mounjaro is right for you, speak to our prescribers through a free consultation, reviewed the same day, with no subscription and no hidden fees.